10/7/2005

~~10169415.7~~ Page 1

12/15/04

1624

Welcome to STN International! Enter x:x

LOGINID:ssspta1611sxp

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	SEP 01	New pricing for the Save Answers for SciFinder Wizard within STN Express with Discover!
NEWS	4	OCT 28	KOREAPAT now available on STN
NEWS	5	NOV 18	Current-awareness alerts, saved answer sets, and current search transcripts to be affected by CERAB, COMPUAB, ELCOM, and SOLIDSTATE reloads
NEWS	6	NOV 30	PHAR reloaded with additional data
NEWS	7	DEC 01	LISA now available on STN
NEWS	8	DEC 09	12 databases to be removed from STN on December 31, 2004

NEWS EXPRESS	OCTOBER 29 CURRENT WINDOWS VERSION IS V7.01A, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 11 AUGUST 2004
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 09:52:36 ON 14 DEC 2004

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 09:52:58 ON 14 DEC 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

12/15/04

Patel

<~~12/2/2004~~>

STRUCTURE FILE UPDATES: 13 DEC 2004 HIGHEST RN 796963-46-7
DICTIONARY FILE UPDATES: 13 DEC 2004 HIGHEST RN 796963-46-7

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading c:\program files\stnexp\queries\10720021.1

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 Cb,Hy

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss full
FULL SEARCH INITIATED 09:53:18 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 113987 TO ITERATE

100.0% PROCESSED 113987 ITERATIONS 1214 ANSWERS
SEARCH TIME: 00.00.03

L2 1214 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION

FULL ESTIMATED COST 155.42 155.63

FILE 'CAPLUS' ENTERED AT 09:53:27 ON 14 DEC 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 14 Dec 2004 VOL 141 ISS 25
FILE LAST UPDATED: 13 Dec 2004 (20041213/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l2
L3 10 L2

=> d l3 fbib hitstr abs total

L3 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:58083 CAPLUS
DN 138:122660
TI Preparation of piperazine oximes as neurokinin NK-1 receptor antagonists
IN Van Maarseveen, Jan H.; Van Scharrenburg, Gustaaf J. M.; Tulp, Martinus Th. M.; McCreary, Andrew C.; Iwema Bakker, Wouter I.; Coolen, Hein K. A. C.; Herremans, Arnoldus H. J.; Van den Hoogenband, Adrianus
PA Solvay Pharmaceuticals B.V., Neth.
SO PCT Int. Appl., 39 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003006459	A1	20030123	WO 2002-EP7472	20020703
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
			EP 2001-202631	A 20010709
EP 1406894	A1	20040414	EP 2002-784838	20020703

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK

			EP 2001-202631	A	20010709
			WO 2002-EP7472	W	20020703
BR 2002010080	A	20040622	BR 2002-10080		20020703
			EP 2001-202631	A	20010709
			WO 2002-EP7472	W	20020703
JP 2004536851	T2	20041209	JP 2003-512231		20020703
			EP 2001-202631	A	20010709
			WO 2002-EP7472	W	20020703
US 2004176389	A1	20040909	US 2003-480542		20031212
			EP 2001-202631	A	20010709
			WO 2002-EP7472	W	20020703

OS MARPAT 138:122660

IT **489437-44-7P 489437-45-8P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of piperazine oximes as neurokinin NK-1 receptor antagonists)

RN 489437-44-7 CAPLUS

CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-4-[[4,5-dihydro-5-(4-morpholinylmethyl)-1,2-benzisoxazol-3-yl]methyl]-2-(1H-indol-3-ylmethyl)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 489437-45-8 CAPLUS

CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-4-[[4,5-dihydro-5-(4-morpholinylmethyl)-1,2-benzisoxazol-3-yl]methyl]-2-(1H-indol-3-ylmethyl)-, monohydrochloride, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

IT **489437-59-4P 489437-60-7P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of piperazine oximes as neurokinin NK-1 receptor antagonists)

RN 489437-59-4 CAPLUS

CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-2-(1H-indol-3-ylmethyl)-4-[3-(2-methyl-1,3-dioxolan-2-yl)propyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 489437-60-7 CAPLUS

CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-4-[2-(1,3-dioxol-2-yl)ethyl]-2-(1H-indol-3-ylmethyl)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



GI



I



II

AB Title compds. [I; X = Ph, pyridyl substituted with 1-2 Me, CF3, OMe, halo, cyano, 5-CF3-tetrazol-1-yl; Y = 2- or 3-indolyl, Ph, 7-azaindol-3-yl, 3-indazolyl, 2-naphthyl, 3-benzo[b]thiophenyl, 2-benzofuranyl, which may be substituted with ≥1 halo or alkyl; n = 0-3; m = 0-2; R1 = NH2, NH-alkyl, dialkylN, morpholino, or morpholino substituted with 1-2 Me and/or methoxymethyl groups, thiomorpholino, 1,1-dioxothiomorpholino, 2-, 3-, 4-pyridyl, 4-methylpiperazinyl; R2 = H, alkyl, Ph, or R2 together with (CH2)m wherein m = 1, and the intermediate C, N, and O atoms forms an isoxazolyl, 4,5-dihydroisoxazolyl; R3, R4 = H, Me; or R3R4 = O], were prepared Thus, (2R)-1-[3,5-bis(trifluoromethyl)benzoyl]-1-(1H-indol-3-ylmethyl)-4-(2-propanon-1-yl)piperazine, O-[2-

(dimethylamino)ethyl]hydroxylamine dihydrochloride, and NaOAc were refluxed together for 2 h in MeOH to give >95% title compound (II). Several I are said to be active in the neurokinin-agonist induced gerbil foot tapping assay.

RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:87194 CAPLUS
DN 136:134787
TI N-Triazolylmethylpiperazine derivatives as neurokinin receptor antagonists
IN Jasserand, Daniel; Schoen, Uwe; Sann, Holger; Brueckner, Reinhard; Eeckhout, Christian
PA Solvay Pharmaceuticals G.m.b.H., Germany
SO Eur. Pat. Appl., 26 pp.
CODEN: EPXXDW
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1176144	A1	20020130	EP 2001-117433	20010719
	EP 1176144	B1	20030709		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
				DE 2000-10036818 A	20000728
	DE 10036818	A1	20020207	DE 2000-10036818	20000728
	CN 1335316	A	20020213	CN 2001-122826	20010710
				DE 2000-10036818 A	20000728
	ZA 2001005737	A	20020122	ZA 2001-5737	20010712
				DE 2000-10036818 A	20000728
	NZ 513041	A	20021220	NZ 2001-513041	20010718
				DE 2000-10036818 A	20000728
	AT 244716	E	20030715	AT 2001-117433	20010719
				DE 2000-10036818 A	20000728
	PT 1176144	T	20031128	PT 2001-117433	20010719
				DE 2000-10036818 A	20000728
	ES 2201007	T3	20040316	ES 2001-1117433	20010719
				DE 2000-10036818 A	20000728
	JP 2002053577	A2	20020219	JP 2001-224792	20010725
				DE 2000-10036818 A	20000728
	CA 2354213	AA	20020128	CA 2001-2354213	20010726
				DE 2000-10036818 A	20000728
	BR 2001003048	A	20020402	BR 2001-3048	20010726
				DE 2000-10036818 A	20000728
	NO 2001003709	A	20020129	NO 2001-3709	20010727
				DE 2000-10036818 A	20000728
	US 2002065276	A1	20020530	US 2001-915558	20010727
	US 6407106	B2	20020618		
				DE 2000-10036818 A	20000728

OS MARPAT 136:134787
IT **393101-98-9P 393102-02-8P 393102-04-0P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of N-triazolylmethylpiperazine derivs. as neurokinin receptor antagonists)
RN 393101-98-9 CAPLUS
CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-2-(1H-indol-3-ylmethyl)-4-

[[5-(4-morpholinylmethyl)-2H-1,2,3-triazol-4-yl]methyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

PAGE 1-A



PAGE 2-A



RN 393102-02-8 CAPLUS
CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-2-[(1-methyl-1H-indol-3-yl)methyl]-4-[[5-(4-morpholinylmethyl)-2H-1,2,3-triazol-4-yl]methyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



RN 393102-04-0 CAPLUS
CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-4-[[5-[(dimethylamino)methyl]-2H-1,2,3-triazol-4-yl]methyl]-2-(1H-indol-3-ylmethyl)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **393102-00-6P 393102-06-2P 393102-08-4P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-triazolylmethylpiperazine derivs. as neurokinin receptor antagonists)
RN 393102-00-6 CAPLUS
CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-2-(1H-indol-3-ylmethyl)-4-[[5-(1-piperazinylmethyl)-2H-1,2,3-triazol-4-yl]methyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



RN 393102-06-2 CAPLUS
CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-4-[[5-[(diethylamino)methyl]-2H-1,2,3-triazol-4-yl]methyl]-2-(1H-indol-3-ylmethyl)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 393102-08-4 CAPLUS
CN Piperazine, 4-[[5-[[bis(1-methylethyl)amino]methyl]-2H-1,2,3-triazol-4-yl]methyl]-1-[3,5-bis(trifluoromethyl)benzoyl]-2-(1H-indol-3-ylmethyl)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **393102-21-1P 393102-23-3P 393183-40-9P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-triazolylmethylpiperazine derivs. as neurokinin receptor antagonists)
RN 393102-21-1 CAPLUS

CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-2-[(1-methyl-1H-indol-3-yl)methyl]-4-[[5-(4-morpholinylmethyl)-2H-1,2,3-triazol-4-yl]methyl]-, dihydrochloride, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



● 2 HCl

RN 393102-23-3 CAPLUS
CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-4-[[5-[(dimethylamino)methyl]-2H-1,2,3-triazol-4-yl]methyl]-2-(1H-indol-3-ylmethyl)-, dihydrochloride, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● 2 HCl

RN 393183-40-9 CAPLUS
CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-2-(1H-indol-3-ylmethyl)-4-[[5-(4-morpholinylmethyl)-2H-1,2,3-triazol-4-yl]methyl]-, dihydrochloride, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

PAGE 1-A



PAGE 2-A



●2 HCl

GI



I

AB Triazolylmethylpiperazines I [R1 = H, alkyl; R2, R3 = (un)substituted alkyl, cycloalkyl; NR2R3 = (un)substituted heterocyclic]were prepared for use as NK-1 receptor antagonists. Thus, (2R)-I [R1 = H, NR2R3 = morpholino] was prepared by treating (2R)-1-[3,5-bis(trifluoromethyl)benzoyl]-2-(1H-indol-3-ylmethyl)piperazine with ClCH2C.tplbond.CCH2Cl, followed by conversion to the azide, and treatment with morpholine. This compound had pEC50 for NK-1 antagonism in isolated guinea pig aorta.

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:923793 CAPLUS
DN 136:53766
TI Process for the preparation of a piperazine derivative as neurokinin antagonist
IN Koga, Keiichi; Orii, Ryoki; Fujii, Yosuke; Goto, Shunsuke; Hirabayashi, Satoshi
PA Fujisawa Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 26 pp.
CODEN: PIXXD2
DT Patent

LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI WO 2001096332	A1	20011220	WO 2001-JP4884		20010608
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
			JP 2000-176210	A	20000613
AU 2001064231	A5	20011224	AU 2001-64231		20010608
			JP 2000-176210	A	20000613
			WO 2001-JP4884	W	20010608
CA 2412873	AA	20021213	CA 2001-2412873		20010608
			JP 2000-176210	A	20000613
			WO 2001-JP4884	W	20010608
EP 1295882	A1	20030326	EP 2001-938576		20010608
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
			JP 2000-176210	A	20000613
			WO 2001-JP4884	W	20010608
US 2003153753	A1	20030814	US 2002-297592		20021213
			JP 2000-176210	A	20000613
			WO 2001-JP4884	W	20010608

OS CASREACT 136:53766
IT **381223-96-7P**
RL: IMF (Industrial manufacture); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(process for preparation of piperazine derivative as neurokinin antagonist)
RN 381223-96-7 CAPLUS
CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-2-[(3-hydroxy-4-methylphenyl)methyl]-4-[2-[(2S)-2-(methoxymethyl)-4-morpholinyl]ethyl]-, dihydrochloride, hydrate (2:3), (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

PAGE 1-A



●2 HCl

PAGE 2-A

●3/2 H_2O

IT **277299-25-9P**
RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(process for preparation of piperazine derivative as neurokinin antagonist)
RN 277299-25-9 CAPLUS
CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-2-[(3-hydroxy-4-methylphenyl)methyl]-4-[2-[(2S)-2-(methoxymethyl)-4-morpholinyl]ethyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT **276857-18-2P**
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(process for preparation of piperazine derivative as neurokinin antagonist)
RN 276857-18-2 CAPLUS
CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-2-[(3-hydroxy-4-methylphenyl)methyl]-4-[2-[(2S)-2-(methoxymethyl)-4-morpholinyl]ethyl]-, dihydrochloride, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



●2 HCl

AB (2R)-1-[3,5-Bis(trifluoromethyl)benzoyl]-4-[2-[(2S)-2-(methoxymethyl)morpholino]ethyl]-2-(3-hydroxy-4-methylbenzyl)piperazine dihydrochloride, useful as neurokinin antagonist (no data), is prepared from (2R)-4-benzyl-1-[3,5-bis(trifluoromethyl)benzoyl]-2-(3-hydroxy-4-methylbenzyl)piperazine via debenzylation, N-alkylation, and conversion into hydrochloride.
RE.CNT 55 THERE ARE 55 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2000:641466 CAPLUS
DN 133:350193
TI Non-amide-based combinatorial libraries derived from N-BOC-iminodiacetic acid: solution-phase synthesis of piperazinone libraries with activity against LEF-1/β-catenin-mediated transcription
AU Boger, Dale L.; Goldberg, Joel; Satoh, Shigeki; Ambroise, Yves; Cohen, Steven B.; Vogt, Peter K.
CS Department of Chemistry and The Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, CA, 92037, USA
SO Helvetica Chimica Acta (2000), 83(8), 1825-1845
CODEN: HCACAV; ISSN: 0018-019X
PB Verlag Helvetica Chimica Acta
DT Journal
LA English
IT **305325-55-7P 305325-56-8P 305325-57-9P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of non-amide-based combinatorial libraries derived from N-BOC-iminodiacetic acid and solution-phase synthesis of piperazinone libraries with activity against lymphoid-enhancer factor-1/β-catenin-mediated transcription)

RN 305325-55-7 CAPLUS
CN Piperazinone, 1-(2-furanylmethyl)-4-(4-methoxybenzoyl)-6-(phenylmethyl)-(9CI) (CA INDEX NAME)



RN 305325-56-8 CAPLUS
CN Piperazinone, 1-(2-furanylmethyl)-4-(4-methylbenzoyl)-6-(phenylmethyl)-(9CI) (CA INDEX NAME)



RN 305325-57-9 CAPLUS
CN Piperazinone, 4-(4-chlorobenzoyl)-1-(2-furanylmethyl)-6-(phenylmethyl)-(9CI) (CA INDEX NAME)



AB The development of a solution-phase approach to the rapid, parallel synthesis of highly functionalized piperazinones in only four steps starting from N-BOC-iminodiacetic acid is detailed. The efforts represent the extension of the solution-phase synthesis of combinatorial libraries from N-BOC-iminodiacetic acid to non-amide-based libraries where simple liquid-liquid extns. are employed to purify all reaction products. This methodol. was applied to the synthesis of a diverse 150-member library

with substituents in three positions of the piperazinone core. Screening results from a luciferase reporter assay indicate that a number of library members are novel repressors of LEF-1/β-catenin-mediated transcription, and may be effective agents against colorectal tumors. Two secondary libraries (100 members each) designed from these lead structures were synthesized and screened, providing addnl. active agents and insight into key structure-activity relationships in the series. These compds. represent only the second class of small mols. which repress transcription of reporter genes containing LEF-1 responsive elements, and the first group not based on DNA minor-groove-binding agents.

RE.CNT 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2000:421138 CAPLUS
DN 133:58814
TI Preparation of piperazines for treating or preventing tachykinin-mediated diseases
IN Take, Kazuhiko; Konishi, Nobukiyo; Shigenaga, Shinji; Kayakiri, Natsuko; Azami, Hidenori; Eikyu, Yoshiteru; Nakai, Kazuo; Ishida, Junya; Morita, Masataka
PA Fujisawa Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 245 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000035915	A1	20000622	WO 1999-JP6943	19991210
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
			AU 1998-7706 A	19981214
			AU 1999-3568 A	19991021
CA 2354875	AA	20000622	CA 1999-2354875	19991210
			AU 1998-7706 A	19981214
			AU 1999-3568 A	19991021
			WO 1999-JP6943 W	19991210
EP 1140924	A1	20011010	EP 1999-959751	19991210
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
			AU 1998-7706 A	19981214
			AU 1999-3568 A	19991021
			WO 1999-JP6943 W	19991210
TR 200101649	T2	20011022	TR 2001-200101649	19991210
			AU 1998-7706 A	19981214
			AU 1999-3568 A	19991021
BR 9917047	A	20020730	BR 1999-17047	19991210
			AU 1998-7706 A	19981214
			AU 1999-3568 A	19991021
			WO 1999-JP6943 W	19991210
JP 2002532499	T2	20021002	JP 2000-588175	19991210

JP 3454427	B2	20031006			
			AU 1998-7706	A	19981214
			AU 1999-3568	A	19991021
			WO 1999-JP6943	W	19991210
JP 2003238563	A2	20030827	JP 2003-23481		19991210
			AU 1998-7706	A	19981214
			AU 1999-3568	A	19991021
			JP 2000-588175	A3	19991210
AU 768652	B2	20031218	AU 2000-16837		19991210
			AU 1998-7706	A	19981214
			AU 1999-3568	A	19991021
			WO 1999-JP6943	W	19991210
TW 509688	B	20021111	TW 1999-88121878		19991214
			AU 1998-7706	A	19981214
			AU 1999-3568	A	19991021
ZA 2001004597	A	20020905	ZA 2001-4597		20010605
			AU 1998-7706	A	19981214

OS MARPAT 133:58814

IT **276857-11-5P 276857-18-2P 276857-20-6P**
276858-29-8P 276858-67-4P 276858-84-5P
276858-90-3P 276859-60-0P 276859-61-1P
276859-62-2P 276859-63-3P 276859-64-4P
276859-70-2P 276859-85-9P 276860-42-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of piperazines for treating or preventing tachykinin-mediated diseases)

RN 276857-11-5 CAPLUS

CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-2-[[3-[(2-methoxyethoxy)methoxy]-4-methylphenyl]methyl]-4-[2-[(3R)-3-(methoxymethyl)-4-morpholinyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 276857-18-2 CAPLUS

CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-2-[(3-hydroxy-4-methylphenyl)methyl]-4-[2-[(2S)-2-(methoxymethyl)-4-morpholinyl]ethyl]-, dihydrochloride, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● 2 HCl

RN 276857-20-6 CAPLUS
CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-2-[[3-[(2-methoxyethoxy)methoxy]-4-methylphenyl]methyl]-4-[3-(3-pyridinyl)-2-propynyl]- (9CI) (CA INDEX NAME)



RN 276858-29-8 CAPLUS
CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-4-[(3-bromo-1,2,4-oxadiazol-5-yl)methyl]-2-[[3-[(2-methoxyethoxy)methoxy]-4-methylphenyl]methyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 276858-67-4 CAPLUS
CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-2-[[3-[(2-methoxyethoxy)methoxy]-4-methylphenyl]methyl]-4-[[1-(triphenylmethyl)-1H-pyrazol-4-yl]methyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 276858-84-5 CAPLUS
CN Piperazine, 1-[3-[(2,5-dimethyl-1H-pyrrol-1-yl)sulfonyl]-5-(trifluoromethyl)benzoyl]-2-[(3-hydroxy-4-methylphenyl)methyl]-4-[2-[(2S)-2-(methoxymethyl)-4-morpholinyl]ethyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 276858-90-3 CAPLUS
CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-2-[(3-hydroxy-4-methylphenyl)methyl]-4-[4-[(2S)-2-(methoxymethyl)-4-morpholinyl]-2-butynyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 276859-60-0 CAPLUS
CN Methanesulfonic acid, trifluoro-, 5-[[(2R)-1-[3,5-bis(trifluoromethyl)benzoyl]-4-[2-[(2S)-2-(methoxymethyl)-4-morpholinyl]ethyl]-2-piperazinyl]methyl]-2-methylphenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 276859-61-1 CAPLUS
CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-2-[[3-[(diphenylmethylene)amino]-4-methylphenyl]methyl]-4-[2-[(2S)-2-(methoxymethyl)-4-morpholinyl]ethyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 276859-62-2 CAPLUS
CN Piperazine, 2-[(3-amino-4-methylphenyl)methyl]-1-[3,5-bis(trifluoromethyl)benzoyl]-4-[2-[(2S)-2-(methoxymethyl)-4-morpholinyl]ethyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 276859-63-3 CAPLUS
CN Piperazine, 2-[(3-amino-4-methylphenyl)methyl]-1-[3,5-bis(trifluoromethyl)benzoyl]-4-[2-[(2S)-2-(methoxymethyl)-4-morpholinyl]ethyl]-, trihydrochloride, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



● 3 HCl

RN 276859-64-4 CAPLUS
CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-2-[[3-[[(2,5-dioxo-1-pyrrolidinyl)methyl]amino]-4-methylphenyl]methyl]-4-[2-[(2S)-2-(methoxymethyl)-4-morpholinyl]ethyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 276859-70-2 CAPLUS
CN Acetamide, N-[5-[[(2R)-1-[3,5-bis(trifluoromethyl)benzoyl]-4-[2-[(2S)-2-(methoxymethyl)-4-morpholinyl]ethyl]-2-piperazinyl]methyl]-2-methylphenyl]-2,2,2-trifluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 276859-85-9 CAPLUS
CN Benzoic acid, 4-[[(2R)-1-[3,5-bis(trifluoromethyl)benzoyl]-4-[2-[(2S)-2-(methoxymethyl)-4-morpholinyl]ethyl]-2-piperazinyl]methyl]-2-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 276860-42-5 CAPLUS
CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-2-[[3-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-4-(1-hydroxy-1-methylethyl)phenyl]methyl]-4-[2-[(2S)-2-(methoxymethyl)-4-morpholinyl]ethyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 276857-12-6P 276857-13-7P 276857-14-8P
276857-15-9P 276857-16-0P 276857-17-1P
276857-19-3P 276857-21-7P 276857-22-8P
276857-23-9P 276857-24-0P 276857-25-1P
276857-26-2P 276857-27-3P 276857-28-4P
276857-29-5P 276857-30-8P 276857-31-9P
276857-32-0P 276857-33-1P 276857-34-2P
276857-35-3P 276857-36-4P 276857-37-5P
276857-38-6P 276857-39-7P 276857-40-0P

276857-41-1P 276857-42-2P 276857-43-3P
276857-44-4P 276857-45-5P 276857-46-6P
276857-47-7P 276857-48-8P 276857-49-9P
276857-50-2P 276857-51-3P 276857-52-4P
276857-53-5P 276857-54-6P 276857-55-7P
276857-56-8P 276857-57-9P 276857-58-0P
276857-59-1P 276857-60-4P 276857-61-5P
276857-62-6P 276857-63-7P 276857-64-8P
276857-65-9P 276857-66-0P 276857-67-1P
276857-68-2P 276857-69-3P 276857-70-6P
276857-71-7P 276857-72-8P 276857-73-9P
276857-74-0P 276857-75-1P 276857-76-2P
276857-77-3P 276857-78-4P 276857-79-5P
276857-80-8P 276857-81-9P 276857-82-0P
276857-83-1P 276857-84-2P 276857-85-3P
276857-86-4P 276857-87-5P 276857-88-6P
276857-89-7P 276857-90-0P 276857-91-1P
276857-92-2P 276857-93-3P 276857-94-4P
276857-95-5P 276857-96-6P 276857-97-7P
276857-98-8P 276857-99-9P 276858-00-5P
276858-01-6P 276858-02-7P 276858-03-8P
276858-04-9P 276858-05-0P 276858-06-1P
276858-07-2P 276858-08-3P 276858-09-4P
276858-10-7P 276858-11-8P 276858-12-9P
276858-13-0P 276858-14-1P 276858-15-2P
276858-16-3P 276858-17-4P 276858-18-5P
276858-19-6P 276858-20-9P 276858-21-0P
276858-22-1P 276858-23-2P 276858-24-3P
276858-25-4P 276858-26-5P 276858-27-6P
276858-28-7P 276858-30-1P 276858-31-2P
276858-32-3P 276858-33-4P 276858-34-5P
276858-35-6P 276858-36-7P 276858-37-8P
276858-38-9P 276858-39-0P 276858-40-3P
276858-41-4P 276858-42-5P 276858-43-6P
276858-44-7P 276858-45-8P 276858-46-9P
276858-47-0P 276858-48-1P 276858-49-2P
276858-50-5P 276858-51-6P 276858-52-7P
276858-53-8P 276858-54-9P 276858-55-0P
276858-56-1P 276858-57-2P 276858-58-3P
276858-59-4P 276858-60-7P 276858-61-8P
276858-62-9P 276858-63-0P 276858-64-1P
276858-65-2P 276858-66-3P 276858-68-5P
276858-69-6P 276858-70-9P 276858-71-0P
276858-72-1P 276858-73-2P 276858-74-3P
276858-75-4P 276858-76-5P 276858-77-6P
276858-78-7P 276858-79-8P 276858-80-1P
276858-81-2P 276858-82-3P 276858-83-4P
276858-85-6P 276858-86-7P 276858-87-8P
276858-88-9P 276858-89-0P 276858-91-4P
276858-92-5P 276858-93-6P 276858-94-7P
276858-95-8P 276858-96-9P 276858-97-0P
276858-98-1P 276858-99-2P 276859-00-8P
276859-01-9P 276859-02-0P 276859-03-1P
276859-04-2P 276859-05-3P 276859-06-4P
276859-07-5P 276859-08-6P 276859-09-7P
276859-10-0P 276859-11-1P 276859-12-2P
276859-13-3P 276859-14-4P 276859-15-5P
276859-16-6P 276859-17-7P 276859-18-8P
276859-19-9P 276859-20-2P 276859-21-3P



I



II

AB The title compds. [I; Y = bond, alkylene; R1 = (un)substituted aryl; R2 = (un)substituted aryl; R3 = H, alkyl; R4 = (3-pyridyl)alkyl, (3-pyridyl)alkenyl; thiazolylalkyl, etc.] and their pharmaceutically acceptable salts, useful for treating or preventing tachykinin-mediated diseases in human being or animals, were prepared E.g., the piperazine cis-II.2HCl showed more than 80% inhibition of 125I-BH-Substance P binding to h-NK1 receptors at 1 mg/kg, and 100% inhibition of emesis in the dog at 0.32 mg/kg.

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1999:9836 CAPLUS
DN 130:81525
TI Preparation of aroylpiperazines as tachykinin antagonists.
IN Miyake, Hiroshi; Take, Kazuhiko; Shigenaga, Shinji; Azami, Hidenori; Sasaki, Hiroshi; Eikyu, Yoshiteru; Nakai, Kazuo; Ishida, Junya; Manabe, Takashi; Konishi, Nobukiyo; Terasaka, Tadashi
PA Fujisawa Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 200 pp.
CODEN: PIXXD2
DT Patent
LA English

Applicants!

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI	WO 9857954	A1	19981223	WO 1998-JP2613		19980615
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG					
				AU 1997-7359	A	19970617
	AU 9876750	A1	19990104	AU 1998-76750		19980615
	AU 743723	B2	20020131			
				AU 1997-7359	A	19970617
				WO 1998-JP2613	W	19980615

EP 993457	A1	20000419	EP 1998-924610		19980615
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI					
			AU 1997-7359	A	19970617
			WO 1998-JP2613	W	19980615
BR 9810146	A	20000808	BR 1998-10146		19980615
			AU 1997-7359	A	19970617
			WO 1998-JP2613	W	19980615
JP 2002504929	T2	20020212	JP 1999-504127		19980615
			AU 1997-7359	A	19970617
			WO 1998-JP2613	W	19980615
ZA 9805255	A	19990106	ZA 1998-5255		19980617
			AU 1997-7359	A	19970617
MX 9911778	A	20000630	MX 1999-11778		19991215
			AU 1997-7359	A	19970617
			WO 1998-JP2613	W	19980615
US 2003114668	A1	20030619	US 2000-446145		20000107
			AU 1997-7359	A	19970617
			WO 1998-JP2613	W	19980615

OS MARPAT 130:81525

IT **218592-67-7P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of aroylpiperazines as tachykinin antagonists)

RN 218592-67-7 CAPLUS

CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-2-[(3,4-dimethylphenyl)methyl]-4-(1H-pyrazol-4-ylmethyl)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **218592-26-8P 218592-27-9P 218592-28-0P**
218592-29-1P 218592-30-4P 218592-31-5P
218592-32-6P 218592-33-7P 218592-34-8P
218592-35-9P 218592-36-0P 218592-37-1P
218592-38-2P 218592-39-3P 218592-40-6P
218592-41-7P 218592-45-1P 218592-46-2P
218592-47-3P 218592-48-4P 218592-49-5P
218592-50-8P 218592-51-9P 218592-52-0P
218592-53-1P 218592-54-2P 218592-55-3P
218592-56-4P 218592-58-6P 218592-64-4P



I



II

AB The invention relates to the compound I, compds. II, their salts, a process for their preparation, pharmaceuticals comprising them, and their use as medicaments [wherein R1 = trihaloalkyl; R2 = trihaloalkyl; R3 = indolylalkyl; A = CH2 or COCH2; R4 = (un)substituted aminothiazolyl, aminopyridinyl, or 1,2,4-thiadiazolyl]. I and II exhibit tachykinin antagonism, especially antagonism of substance P, and neurokinins A and B. For example, (2R)-1-[3,5-bis(trifluoromethyl)benzoyl]-2-(1H-indol-3-ylmethyl)piperazine (prepared in 6 steps) underwent a sequence of (1) N-alkylation with BrCH2CO2CH2Ph, (2) hydrogenolysis of the ester to the acid, (3) amidation using EDC and HOBt, and (4) salification with fumaric acid, to give title compound I as the fumarate salt (III). In a test for inhibition of 125I-BH-substance P binding to h-NK1 receptors, III gave >90% inhibition at 0.1 μg/mL.

L3 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1997:80506 CAPLUS
DN 126:104102
TI Piperazine derivatives useful as tachykinin antagonists.
IN Matsuo, Masaaki; Hagiwara, Daijiro; Manabe, Takashi; Konishi, Nobuyiko; Shigenaga, Shinji; Murano, Kenji; Matsuda, Hiroshi; Miyake, Hiroshi
PA Fujisawa Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 44 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9637488	A1	19961128	WO 1996-JP1334	19960521
	W: JP, US				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
				GB 1995-10600 A	19950525
	EP 828730	A1	19980318	EP 1996-915199	19960521
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
				GB 1995-10600 A	19950525
				WO 1996-JP1334 W	19960521

JP 11505829	T2	19990525	JP 1996-535552		19960521
			GB 1995-10600	A	19950525
			WO 1996-JP1334	W	19960521
US 5939413	A	19990817	US 1997-952112		19971124
			GB 1995-10600	A	19950525
			WO 1996-JP1334	W	19960521

OS MARPAT 126:104102

IT **185750-92-9P 185750-95-2P 185751-01-3P**
185751-04-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of piperazine derivs. as tachykinin antagonists)

RN 185750-92-9 CAPLUS

CN 1H-1,4-Diazepine, 1-[[4-[3,5-bis(trifluoromethyl)benzoyl]-5-(1H-indol-3-ylmethyl)-2-oxo-1-piperazinyl]acetyl]hexahydro-4-methyl-, monohydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 185750-95-2 CAPLUS

CN Piperazinone, 1-(2-[1,4'-bipiperidin]-1'-yl-2-oxoethyl)-4-[3,5-bis(trifluoromethyl)benzoyl]-5-(1H-indol-3-ylmethyl)-, monohydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 185751-01-3 CAPLUS
CN Piperazinone, 1-(4-[1,4'-bipiperidin]-1'-yl-4-oxobutyl)-4-[3,5-bis(trifluoromethyl)benzoyl]-5-(1H-indol-3-ylmethyl)-, monohydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 185751-04-6 CAPLUS
CN 1H-1,4-Diazepine, 1-[4-[4-[3,5-bis(trifluoromethyl)benzoyl]-5-(1H-indol-3-ylmethyl)-2-oxo-1-piperazinyl]-1-oxobutyl]hexahydro-4-methyl-, monohydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

GI



I



II

AB The invention relates to piperazine derivs. I and their pharmaceutically acceptable salts [wherein A, Y = bond, alkylene; R1 = haloalkyl; R2 = (un)substituted indolyl; Z = H, (un)protected CO2H, (un)substituted or derivatized or (hetero)cyclic carbamoyl; n= 0-2]. The invention also relates to processes for preparation of I, to pharmaceutical compns. comprising them, and to their use for treatment of tachykinin-mediated diseases. For instance, cyclization of (1R)-N2-(bromoacetyl)-N2-[3-

L3 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1995:884027 CAPLUS
DN 123:286083
TI Preparation of piperazine-derivative tachykinin antagonists
IN Matsuo, Masaaki; Hagiwara, Daijiro; Manabe, Takashi; Nobukiyo, Konishi; Shigenaga, Shinji; Murano, Kenji; Matsuda, Hiroshi; Miyake, Hiroshi
PA Fujisawa Pharmaceutical Co., Ltd., Japan
SO Eur. Pat. Appl., 114 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 655442	A1	19950531	EP 1994-118542	19941125
	EP 655442	B1	20010523		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
				GB 1993-24479 A	19931129
				GB 1994-2010 A	19940202
				GB 1994-12708 A	19940624
	ZA 9409228	A	19950801	ZA 1994-9228	19941121
				GB 1993-24479 A	19931129
	IL 111730	A1	19981206	IL 1994-111730	19941122
				GB 1993-24479 A	19931129
				GB 1994-2010 A	19940202
				GB 1994-12708 A	19940624
	CA 2136712	AA	19950530	CA 1994-2136712	19941125
				GB 1993-24479 A	19931129
				GB 1994-2010 A	19940202
				GB 1994-12708 A	19940624
	AU 9479111	A1	19950608	AU 1994-79111	19941125
	AU 689504	B2	19980402		
				GB 1993-24479 A	19931129
				GB 1994-2010 A	19940202
				GB 1994-12708 A	19940624
	ES 2156588	T3	20010701	ES 1994-118542	19941125
				GB 1993-24479 A	19931129
				GB 1994-2010 A	19940202
				GB 1994-12708 A	19940624
	PT 655442	T	20010928	PT 1994-118542	19941125
				GB 1993-24479 A	19931129
				GB 1994-2010 A	19940202
				GB 1994-12708 A	19940624
	TW 384287	B	20000311	TW 1994-83111021	19941126
				GB 1993-24479 A	19931129
				GB 1994-2010 A	19940202
				GB 1994-12708 A	19940624
	CN 1107149	A	19950823	CN 1994-117822	19941128
	CN 1041923	B	19990203		
				GB 1993-24479 A	19931129
				GB 1994-12708 A	19940624
	JP 07242641	A2	19950919	JP 1994-293388	19941128

Patel <12/2/2004>

JP 3129123	B2	20010129			
			GB 1993-24479	A	19931129
			GB 1994-2010	A	19940202
			GB 1994-12708	A	19940624
HU 71348	A2	19951128	HU 1994-3414		19941128
			GB 1993-24479	A	19931129
			GB 1994-2010	A	19940202
			GB 1994-12708	A	19940624
US 5670505	A	19970923	US 1994-348176		19941128
			GB 1993-24479	A	19931129
			GB 1994-2010	A	19940202
			GB 1994-12708	A	19940624
BR 9500539	A	19951031	BR 1995-539		19950202
			GB 1994-2010	A	19940202
			GB 1994-12708	A	19940624
US 5883098	A	19990316	US 1997-884039		19970627
			GB 1993-24479	A	19931129
			GB 1994-2010	A	19940202
			GB 1994-12708	A	19940624
			US 1994-348176	A2	19941128
			US 1995-450176	B1	19950525
GR 3035923	T3	20010831	GR 2001-400128		20010524
			GB 1993-24479	A	19931129
			GB 1994-2010	A	19940202
			GB 1994-12708	A	19940624

PATENT FAMILY INFORMATION:

FAN 1997:80507

	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI	WO 9637489	A1	19961128	WO 1996-JP1335		19960521
	W: AU, CA, CN, HU, JP, KR, MX, NZ, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE					
				US 1995-450176	A	19950525
	CA 2222041	AA	19961128	CA 1996-2222041		19960521
				US 1995-450176	A	19950525
	AU 9657031	A1	19961211	AU 1996-57031		19960521
	AU 706021	B2	19990603			
				US 1995-450176	A	19950525
				WO 1996-JP1335	W	19960521
	EP 846116	A1	19980610	EP 1996-915200		19960521
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI					
				US 1995-450176	A	19950525
				WO 1996-JP1335	W	19960521
	CN 1191533	A	19980826	CN 1996-195744		19960521
	CN 1072220	B	20011003			
				US 1995-450176	A	19950525
	JP 11505830	T2	19990525	JP 1996-535553		19960521
	JP 3071829	B2	20000731			
				US 1995-450176	A	19950525
				WO 1996-JP1335	W	19960521
	ZA 9604101	A	19960729	ZA 1996-4101		19960522
				US 1995-450176	A	19950525
	IL 118369	A1	20000601	IL 1996-118369		19960522
				US 1995-450176	A	19950525
	TW 391960	B	20000601	TW 1996-85106105		19960523
				US 1995-450176	A	19950525
	US 5883098	A	19990316	US 1997-884039		19970627
				GB 1993-24479	A	19931129
				GB 1994-2010	A	19940202

GB 1994-12708	A	19940624
US 1994-348176	A2	19941128
US 1995-450176	B1	19950525

OS MARPAT 123:286083

IT **169459-14-7P 169459-18-1P 169459-22-7P**
169459-26-1P 169459-35-2P 169459-36-3P
169459-37-4P 169459-41-0P 169459-51-2P
169459-52-3P 169459-56-7P 169459-57-8P
169459-64-7P 169459-69-2P 169459-70-5P
169459-71-6P 169459-79-4P 169459-82-9P
169459-86-3P 169460-03-1P 169460-04-2P
169460-05-3P 169460-11-1P 169460-19-9P
169460-29-1P 169460-30-4P 169460-31-5P
169460-32-6P 169460-44-0P 169460-45-1P
169460-51-9P 169460-52-0P 169460-87-1P
169460-88-2P 169460-89-3P 169460-90-6P
169460-91-7P 169460-92-8P 169460-93-9P
169460-94-0P 169460-95-1P 169460-96-2P
169460-97-3P 169460-98-4P 169460-99-5P
169461-00-1P 169461-01-2P 169461-02-3P
169461-03-4P 169461-04-5P 169461-05-6P
169461-06-7P 169461-07-8P 169461-08-9P
169461-09-0P 169461-13-6P 169461-17-0P
169461-30-7P 169461-46-5P 169461-47-6P
169461-65-8P 169461-66-9P 169461-78-3P
169461-89-6P 169461-92-1P 169462-05-9P
169462-06-0P 169462-07-1P 169462-09-3P
169462-10-6P 169462-11-7P 169462-12-8P
169462-13-9P 169462-15-1P 169462-35-5P
169462-46-8P 169462-51-5P 169462-64-0P
169462-71-9P 169462-77-5P 169462-78-6P
169533-35-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of piperazine-derivative tachykinin antagonists)

RN 169459-14-7 CAPLUS

CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-4-[2-(1H-indol-2-yl)ethyl]-2-(phenylmethyl)-, monohydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 169459-18-1 CAPLUS

CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-4-[3-(1H-indol-2-yl)propyl]-2-(phenylmethyl)-, monohydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 169459-22-7 CAPLUS
CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-2-(phenylmethyl)-4-(3-pyridinylmethyl)-, dihydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 169459-26-1 CAPLUS
CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-4-(1H-indol-3-ylacetyl)-2-(phenylmethyl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 169459-35-2 CAPLUS
CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-4-(1H-indol-3-ylcarbonyl)-2-(phenylmethyl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 169459-36-3 CAPLUS
CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-4-[3-(1H-indol-3-yl)-1-oxopropyl]-2-(phenylmethyl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 169459-37-4 CAPLUS
CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-4-[4-(1H-indol-3-yl)-1-oxobutyl]-2-(phenylmethyl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 169459-41-0 CAPLUS
CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-4-[3-(1H-indol-3-yl)-1-oxo-2-propenyl]-2-(phenylmethyl)-, [R-(E)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 169459-51-2 CAPLUS
CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-4-[1-oxo-3-(3-pyridinyl)-2-propenyl]-2-(phenylmethyl)-, [R-(E)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 169459-52-3 CAPLUS
CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-4-[3-(3-furanyl)-1-oxo-2-propenyl]-2-(phenylmethyl)-, [R-(E)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 169459-56-7 CAPLUS
CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-4-[1-oxo-3-(3-thienyl)-2-propenyl]-2-(phenylmethyl)-, [R-(E)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 169459-57-8 CAPLUS
CN Acetamide, N-[4-[3-[4-[3,5-bis(trifluoromethyl)benzoyl]-3-(phenylmethyl)-1-piperazinyl]-3-oxo-1-propenyl]-2-thiazolyl]-, [R-(E)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 169459-64-7 CAPLUS
CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-2-[(3,4-dimethylphenyl)methyl]-4-[1-oxo-3-(3-pyridinyl)-2-propenyl]-, [R-(E)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 169459-69-2 CAPLUS
CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-2-(phenylmethyl)-4-(3-pyridinylacetyl)-, monohydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 169459-70-5 CAPLUS
CN Piperazine, 4-(2-benzofuranylcarbonyl)-1-[3,5-bis(trifluoromethyl)benzoyl]-2-(phenylmethyl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 169459-71-6 CAPLUS
CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-2-(phenylmethyl)-4-(3-pyridinylcarbonyl)-, monohydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 169459-79-4 CAPLUS
CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-2-(1H-indol-3-ylmethyl)-4-(3-pyridinylcarbonyl)-, monohydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 169459-82-9 CAPLUS
CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-2-(1H-indol-3-ylmethyl)-4-[1-oxo-3-(3-pyridinyl)-2-propenyl]-, [R-(E)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 169459-86-3 CAPLUS
CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-2-[(3,4-dimethylphenyl)methyl]-4-(3-pyridinylcarbonyl)-, monohydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 169460-03-1 CAPLUS
CN Acetamide, N-[4-[3-[4-[3,5-bis(trifluoromethyl)benzoyl]-3-[(3,4-dimethylphenyl)methyl]-1-piperazinyl]-3-oxo-1-propenyl]-2-thiazolyl]-, [R-(E)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 169460-04-2 CAPLUS
CN Acetamide, N-[4-[3-[4-[3,5-bis(trifluoromethyl)benzoyl]-3-(1H-indol-3-ylmethyl)-1-piperazinyl]-3-oxo-1-propenyl]-2-thiazolyl]-, [R-(E)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 169460-05-3 CAPLUS
CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-4-(1H-indol-3-ylmethyl)-2-(phenylmethyl)-, monohydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 169460-11-1 CAPLUS
CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-4-[(1-methyl-1H-indol-3-yl)methyl]-2-(phenylmethyl)-, monohydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 169460-19-9 CAPLUS
CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-2-[(3,4-dimethylphenyl)methyl]-4-[1-oxo-3-(3-pyridinyl)-2-propenyl]-, monohydrochloride, [R-(E)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



● HCl

RN 169460-29-1 CAPLUS
CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-2-(1H-indol-3-ylmethyl)-4-[oxo[4-(triphenylmethyl)-1-piperazinyl]acetyl]-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 169460-30-4 CAPLUS
CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-4-[3-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)propyl]-2-[(3,4-dimethylphenyl)methyl]-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 169460-31-5 CAPLUS
CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-2-[(3,4-dimethylphenyl)methyl]-4-[2-oxo-2-(3-pyridinyl)ethyl]-, monohydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 169460-32-6 CAPLUS
CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-4-[2-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)ethyl]-2-[(3,4-dimethylphenyl)methyl]-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 169460-44-0 CAPLUS
CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-2-[(3,4-dimethylphenyl)methyl]-4-[1-oxo-3-(2-thienyl)-2-propenyl]-, [R-(E)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 169460-45-1 CAPLUS
CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-2-(1H-indol-3-ylmethyl)-4-(pyrazinylcarbonyl)-, dihydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 169460-51-9 CAPLUS
CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-2-[(3,4-dimethylphenyl)methyl]-4-(3-pyridinylacetyl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 169460-52-0 CAPLUS
CN Piperazine, 1-(3,5-dimethylbenzoyl)-2-[(3,4-dimethylphenyl)methyl]-4-[1-oxo-3-(3-pyridinyl)-2-propenyl]-, [R-(E)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 169460-87-1 CAPLUS
CN 1-Piperazineethanol, 4-[[4-[3,5-bis(trifluoromethyl)benzoyl]-3-(1H-indol-3-ylmethyl)-1-piperazinyl]acetyl]-, dihydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 169460-88-2 CAPLUS
CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-2-(1H-indol-3-ylmethyl)-4-[2-oxo-2-[4-(2-pyridinyl)-1-piperazinyl]ethyl]-, trihydrochloride, (R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



●3 HCl

RN 169460-89-3 CAPLUS
CN Piperazine, 4-[2-(4-acetyl-1-piperazinyl)-2-oxoethyl]-1-[3,5-bis(trifluoromethyl)benzoyl]-2-(1H-indol-3-ylmethyl)-, monohydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 169460-90-6 CAPLUS
CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-2-(1H-indol-3-ylmethyl)-4-[2-oxo-2-(4-phenyl-1-piperazinyl)ethyl]-, dihydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 169460-91-7 CAPLUS
CN Piperazine, 4-[2-(1,4'-bipiperidin-1'-yl)-2-oxoethyl]-1-[3,5-bis(trifluoromethyl)benzoyl]-2-(1H-indol-3-ylmethyl)-, dihydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 169460-92-8 CAPLUS
CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-4-[2-(4-cyclohexyl-1-piperazinyl)-2-oxoethyl]-2-(1H-indol-3-ylmethyl)-, dihydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 169460-93-9 CAPLUS
CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-2-(1H-indol-3-ylmethyl)-4-[2-oxo-2-(4-propyl-1-piperazinyl)ethyl]-, dihydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● 2 HCl

RN 169460-94-0 CAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[[4-[3,5-bis(trifluoromethyl)benzoyl]-3-(1H-indol-3-ylmethyl)-1-piperazinyl]acetyl]-, monohydrochloride, [S-(R*,S*)]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 169460-95-1 CAPLUS
CN Acetamide, N-[1-[[4-[3,5-bis(trifluoromethyl)benzoyl]-3-(1H-indol-3-ylmethyl)-1-piperazinyl]acetyl]-4-phenyl-4-piperidinyl]-, monohydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 169460-96-2 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[[4-[3,5-bis(trifluoromethyl)benzoyl]-3-(1H-indol-3-ylmethyl)-1-piperazinyl]acetyl]-, ethyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 169460-97-3 CAPLUS
CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-2-(1H-indol-3-ylmethyl)-4-[2-oxo-2-(4-oxo-1-piperidinyl)ethyl]-, monohydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 169460-98-4 CAPLUS
CN 3-Piperidinecarboxamide, 1-[[4-[3,5-bis(trifluoromethyl)benzoyl]-3-(1H-indol-3-ylmethyl)-1-piperazinyl]acetyl]-, monohydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

● HCl

RN 169460-99-5 CAPLUS
CN Acetamide, N-[1-[[4-[3,5-bis(trifluoromethyl)benzoyl]-3-[(3,4-dimethylphenyl)methyl]-1-piperazinyl]acetyl]-4-phenyl-4-piperidinyl]-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 169461-00-1 CAPLUS
CN Morpholine, 4-[[4-[3,5-bis(trifluoromethyl)benzoyl]-3-[(3,4-dimethylphenyl)methyl]-1-piperazinyl]acetyl]-, monohydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 169461-01-2 CAPLUS
CN Acetamide, N-[1-[2-[4-[3,5-bis(trifluoromethyl)benzoyl]-3-[(3,4-dimethylphenyl)methyl]-1-piperazinyl]-2-oxoethyl]-4-phenyl-4-piperidinyl]-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 169461-02-3 CAPLUS
CN 4-Piperidinecarboxamide, 1-[[4-[3,5-bis(trifluoromethyl)benzoyl]-3-(1H-indol-3-ylmethyl)-1-piperazinyl]acetyl]-, monohydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 169461-03-4 CAPLUS
CN 1H-1,4-Diazepine, 1-[[4-[3,5-bis(trifluoromethyl)benzoyl]-3-(1H-indol-3-ylmethyl)-1-piperazinyl]acetyl]hexahydro-4-methyl-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 169461-04-5 CAPLUS
CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-4-[2-(4-ethyl-1-piperazinyl)-2-oxoethyl]-2-(1H-indol-3-ylmethyl)-, dihydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● 2 HCl

RN 169461-05-6 CAPLUS
CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-2-(1H-indol-3-ylmethyl)-4-[2-oxo-2-(1-piperidinyl)ethyl]-, monohydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 169461-06-7 CAPLUS
CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-2-(1H-indol-3-ylmethyl)-4-[2-oxo-2-(4-phenyl-1-piperidinyl)ethyl]-, monohydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 169461-07-8 CAPLUS
CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-2-(1H-indol-3-ylmethyl)-4-[2-oxo-2-[4-(phenylmethyl)-1-piperidinyl]ethyl]-, monohydrochloride, (R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 169461-08-9 CAPLUS
CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-2-(1H-indol-3-ylmethyl)-4-[2-oxo-2-(1-pyrrolidinyl)ethyl]-, monohydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 169461-09-0 CAPLUS
CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-2-(1H-indol-3-ylmethyl)-4-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 169461-13-6 CAPLUS
CN 1H-1,4-Diazepine, 1-[4-[4-[3,5-bis(trifluoromethyl)benzoyl]-3-(1H-indol-3-ylmethyl)-1-piperazinyl]-1-oxobutyl]hexahydro-4-methyl-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 169461-17-0 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[[4-[3,5-bis(trifluoromethyl)benzoyl]-3-(1H-indol-3-ylmethyl)-1-piperazinyl]acetyl]-, monohydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 169461-30-7 CAPLUS
CN Acetamide, N-[4-[[4-[3,5-bis(trifluoromethyl)benzoyl]-3-[(3,4-dimethylphenyl)methyl]-1-piperazinyl]methyl]-2-thiazolyl]-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 169461-46-5 CAPLUS
CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-2-(1H-indol-3-ylmethyl)-4-[2-oxo-2-(1-piperazinyl)ethyl]-, dihydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 169461-47-6 CAPLUS
CN Piperazine, 1-[3,5-bis(trifluoromethyl)benzoyl]-4-[(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)acetyl]-2-(1H-indol-3-ylmethyl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 169461-65-8 CAPLUS
CN Piperazine, 1-[3,4-bis(trifluoromethyl)benzoyl]-4-[3-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)propyl]-2-(1H-indol-3-ylmethyl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 169461-66-9 CAPLUS
CN Piperazine, 1-[3,4-bis(trifluoromethyl)benzoyl]-4-[4-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)butyl]-2-(1H-indol-3-ylmethyl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 169461-78-3 CAPLUS
CN Piperazine, 1-[3,4-bis(trifluoromethyl)benzoyl]-2-(1H-indol-3-ylmethyl)-4-[4-(4-methyl-1-piperazinyl)-4-oxobutyl]-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 169461-89-6 CAPLUS
CN Piperazine, 1-[3,4-bis(trifluoromethyl)benzoyl]-2-(1H-indol-3-ylmethyl)-4-[1-methyl-2-(4-methyl-1-piperazinyl)-2-oxoethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● HCl

RN 169461-92-1 CAPLUS
CN 1H-1,4-Diazepine, 1-[[4-[3,4-bis(trifluoromethyl)benzoyl]-3-(1H-indol-3-ylmethyl)-1-piperazinyl]acetyl]hexahydro-4-methyl-, (R)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 169461-91-0
CMF C30 H33 F6 N5 O2

Absolute stereochemistry.



CM 2

CRN 77-92-9
CMF C6 H8 O7



RN 169462-05-9 CAPLUS
CN Piperazine, 1-[3,4-bis(trifluoromethyl)benzoyl]-2-(1H-indol-3-ylmethyl)-4-[4-oxo-4-[4-(phenylmethyl)-1-piperazinyl]butyl]-, monohydrochloride, (R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 169462-06-0 CAPLUS
CN Piperazine, 1-[3,4-bis(trifluoromethyl)benzoyl]-2-(1H-indol-3-ylmethyl)-4-[4-oxo-4-(4-phenyl-1-piperazinyl)butyl]-, dihydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 169462-07-1 CAPLUS
CN Piperazine, 1-[3,4-bis(trifluoromethyl)benzoyl]-4-[4-(4-cyclohexyl-1-piperazinyl)-4-oxobutyl]-2-(1H-indol-3-ylmethyl)-, dihydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 169462-09-3 CAPLUS
CN Piperazine, 1-[3,4-bis(trifluoromethyl)benzoyl]-2-(1H-indol-3-ylmethyl)-4-[4-oxo-4-(1-piperidinyl)butyl]-, monohydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 169462-10-6 CAPLUS
CN Piperazine, 1-[3,4-bis(trifluoromethyl)benzoyl]-2-(1H-indol-3-ylmethyl)-4-[4-oxo-4-[4-(2-pyridinyl)-1-piperazinyl]butyl]-, trihydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●3 HCl

RN 169462-11-7 CAPLUS
CN Piperazine, 1-[3,4-bis(trifluoromethyl)benzoyl]-2-(1H-indol-3-ylmethyl)-4-[4-oxo-4-(4-phenyl-1-piperidinyl)butyl]-, monohydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 169462-12-8 CAPLUS
CN Piperazine, 1-[3,4-bis(trifluoromethyl)benzoyl]-2-(1H-indol-3-ylmethyl)-4-[4-oxo-4-[4-(triphenylmethyl)-1-piperazinyl]butyl]-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 169462-13-9 CAPLUS
CN Piperazine, 1-[3,4-bis(trifluoromethyl)benzoyl]-2-(1H-indol-3-ylmethyl)-4-[4-oxo-4-(1-piperazinyl)butyl]-, dihydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 169462-15-1 CAPLUS
CN 1H-1,4-Diazepine, 1-[4-[4-[3,4-bis(trifluoromethyl)benzoyl]-3-(1H-indol-3-ylmethyl)-1-piperazinyl]-1-oxobutyl]hexahydro-4-methyl-, (R)-, sulfate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 169462-14-0
CMF C32 H37 F6 N5 O2

Absolute stereochemistry.



CM 2

CRN 7664-93-9
CMF H2 O4 S